FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burden										
	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BIBERSTEIN KATHRYN L					2. Issuer Name and Ticker or Trading Symbol Alkermes plc. [ALKS]									neck all app Direc	ationship of Reporting (all applicable) Director		10% Ov	/ner
(Last) 852 WINT	(First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 10/05/2015								Officer (give title Other (specify below) SVP, CLO, Secretary & CCO			·
(Street) WALTHAM MA 02451 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									lual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Table	e I - Nor	n-Deriv	ative	Seci	urities	Acc	quired,	Dis	posed o	f, or Be	neficia	ly Owne	d			
					action Day/Yea	r) Ex	A. Deeme recution any lonth/Day	3. Transa Code (I 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefi Owned	ties cially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		ed ction(s) 3 and 4)			(Instr. 4)
Ordinary S	hares	5/2015	2015		A		5,000	A	\$0	9	98,235		D					
Ordinary Shares 10/09						/2015		F		2,356	D \$59.7		77 9	95,879		D		
		Ta									osed of, onvertik			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	Date, Transact Code (In:					6. Date Expiration (Month/Da	n Date	Amount of		of s ig e Security	8. Price of Derivative Security (Instr. 5)		ve es ally ig d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisal		Expiration Date	Title	Amount or Number of Shares					
Performance Restricted Stock Units	(1)	10/05/2015			A		5,000		(2)		(2)	Ordinary Shares	5,000	\$0	5,000)	D	

Explanation of Responses:

- 1. Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc.
- 2. Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil).

/s/ Jennifer Baptiste, attorney-

in-fact for Kathryn L.

10/07/2015

Biberstein

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.